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Homocysteine is an intermediary product of methionine metabolism. The level of
homocysteine is controlled by two pathways—remethylation and transsulphuration.
Elevated homocysteine level may result from deficiency or impaired function of enzymes
and cofactors in these pathways. Homocystinuria is a rare genetic disease with extreme
hyperhomocysteinemia and is associated with the occurrence of arterial and venous
thrombotic events at young age. Therefore, homocysteine has been considered a risk factor
for vascular diseases.
Plasma homocysteine level is influenced by many factors, genetic as well as environ-
mental. Mild hyperhomocysteinemia is quite common. The role of homocysteine in
venous thrombosis has been studied less extensively than its role in arterial diseases
and nowadays it seems quite controversial. In vitro, it is possible to demonstrate multiple
prothrombotic action of homocysteine. However, the results of epidemiologic studies are
not so clear. Most of them found an association of hyperhomocysteinemia with venous
thromboembolism (VTE) but the association was quite weak and moreover, it was much
weaker in prospective than in retrospective studies. It is not quite clear whether elevated
homocysteine level is the cause of thromboembolic event or the consequence of it. It is
also possible that hyperhomocysteinemia plays a role in the pathogenesis of VTE only as
an additional risk factor in the presence of other thrombophilic disorders.
However, some data confirm hyperhomocysteinemia as a risk factor for recurrent VTE.
Some smaller studies have also found association of hyperhomocysteinemia with venous
thrombosis at unusual sites.
Homocysteine level can be lowered by vitamin supplementation, especially with folic
acid and vitamin B12. So far, the benefit of lowering homocysteine level in primary and
secondary VTE prevention has not been clearly proven.
Currently, there is not enough evidence to support the necessity of testing homo-
cysteine level in VTE patients, neither is sufficient evidence of the benefit of vitamin
supplementation in mild or moderate hyperhomocysteinemia. Therefore, such testing and
supplementation should be performed only in selected cases.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Venous thromboembolism (VTE) is a multifactorial disease, with
many inherited and acquired risk factors and their interaction
playing a role in the etiopathogenesis. One of important risk
factors is thrombophilia. It is defined as a tendency to form
thrombi in veins or arteries but the term is used more frequently
in association with venous thrombosis. Hyperhomocysteinemia
is often included in the list of thrombophilic disorders [1].
However, there is much disagreement concerning the impor-
tance of homocysteine level testing and potential management
of hyperhomocysteinemia in VTE patients.2. Homocysteine metabolism
Homocysteine, a sulfur-containing amino acid, is an inter-
mediary product of methionine metabolism (methionine is
an essential amino acid, abundant in animal proteins).
Homocysteine is formed intracellularly by demethylation of
dietary methionine. Plasma homocysteine level is controlled
by two metabolic pathways – remethylation to methionine
and transsulphuration to cysteine – Fig. 1. Remethylation is
the predominant metabolic pathway which is important for
the regulation of fasting level while transsulphuration path-
way regulates elevated homocysteine levels, e.g. postpran-
dially or after methionine load.
Remethylation has two alternative pathways in humans.
(a) The predominant one is vitamin B12 (cobalamin) depen-
dent, it occurs in all tissues including vascular endothe-
lium. This pathway is connected with folate cycle.
(b) The additional remethylation pathway is less important,
it is bound to hepatocytes.Fig. 1 – Scheme of homocysteine metabolism—according to
Key NS, Mc Glennen RC [4]. 1—catalyzed by cystathionineIn transsulpuration pathway, vitamin B6 is required as a
cofactor [2–4].beta-synthase (CBS). 2—catalyzed by methylentetrahydro-
folate reductase (MTHFR). In the remethylation pathway,
betaine (trimethylglycine) or N-5-methyltetrahydrofolate.
(MTHF) serve as methyl (CH3) group donors. Folic acid is a
source of tetrahydrofolate; vitamin B12 is a cofactor in the
folate cycle. In the transsulphuration pathway, vitamin B6
works as a cofactor.3. Hyperhomocysteinemia and its causes
The determinants of homocysteine level include genetic and
physiologic factors, life style, nutrition, various diseases and
medication. The level increases with age (from childhood toold age approximately doubles), after adolescence it is
slightly higher in men, decreases in pregnancy. Homocystei-
nemia also depends on renal function and creatinine synth-
esis. Healthy life style and sufficient vitamin consumption in
the diet or in the form of vitamin supplements (especially
those containing folic acid) lead to reduction of homocysteine
level, as well as folate-fortified diet (e.g., folate fortification of
grain products, implemented in the US) [5]. However, mild
hyperhomocysteinemia is found in individuals with alterna-
tive diet, vegetarians and vegans, respectively, as a conse-
quence of vitamin B12 deficiency [6]. There are also ethnic
and regional differences in homocysteine level. Therefore,
the reference limits for homocysteinemia should not be
strictly defined but should be interpreted with respect to
the mentioned determinants. The value of 15 mmol/L is
considered as the upper reference limit for the age of 15–65
years; 20 mmol/L for the age above 65 years; and 10 mmol/L for
children and pregnant women while these limits should be
Table 1 – Causes of hyperhomocysteinemia [2,5,7].
Genetic causes 1. CBS deficiency
2. Inherited defects of folate metabolism
3. Inherited defects of cobalamin absorption, transport and metabolism
4. Polymorphisms of folate and cobalamin metabolism, including polymorphisms of following
enzymes:
(a) MTHFR
(b) Methionine synthase
(c) Methionine synthase-reductase
Acquired factors 1. Folate deficiency
2. Vitamin B12 deficiency
3. Vitamin B6 (pyridoxine) deficiency
4. Some diseases and disorders:
(a) Renal insufficiency
(b) Proliferative disorders: malignancy, psoriasis
(c) Rheumatoid arthritis, systemic lupus erythematosus
(d) Hypothyreoidism
5. Some medicaments: sex hormones, insulin, antiepileptics, fibrates, metformin, D-
penicillamine, proton pump inhibitors, methotrexate, L-dopa, 6-mercaptopurin,
sulfasalazin, cyclosporin, megadoses of vitamin C
6. Factors of life style: smoking, alcohol, sedentary life style, high consumption of animal
proteins rich in methionine
7. Other: age, male sex, gastroplasty, Down syndrome, postmenopause
CBS—cystathionine beta-synthase.
MTHFR—methylentetrahydrofolate reductase.
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diet or vitamin supplement use) [5].
The causes of hyperhomocysteinemia may be inherited or
acquired or the combination of both—Table 1.
According to the degree of homocysteine elevation, hyper-
homocysteinemia may be classified as:(1) Mild: 15–30 mmol/L (prevalence in population o10%). Pos-
sible causes may be found in life style but also in
vegeterian diet, polymorphism of methylentetrahydrofo-
late reductase (MTHFR) 677 T, mild folate or cobalamin
deficiency, renal insufficiency, medication influencing
homocysteine metabolism or the level of folate or
cobalamin(2) Moderate: 30–100 mmol/L (prevalenceo1%). It may occur in
moderate to severe folate or cobalamin deficiency or in
renal insufficiency(3) Severe: above 100 mmol/L (prevalenceo0.02%). It may occur
in severe cobalamin deficiency or in homocystinuria [5].
The prevalence of congenital homocystinuria is about
1:200,000–300,000 in general population, most cases
(90–95%) are the consequence of a homozygous defect in
cystathionine beta-synthase (CBS) gene (the rest of cases is
associated with some rare mutations in MTHFR, methionine
synthase or methionine synthase–reductase genes). Homo-
cysteine levels are high, in the range of 100–500 mmol/L. The
disease manifests in most cases in childhood with eye lens
dislocation, myopia, marphanoid habitus, mental retardation
but also VTE and premature atherosclerosis [2,4,8]. Leading
causes of mortality in these patients are VTE, stroke, periph-
eral arterial thrombosis and myocardial infarction [9]. Earlydiagnosis and supplementation of pyridoxine and/or folate
and betaine, optimally since childhood, may prevent cardio-
vascular events and other clinical manifestations [5].
Severe deficiency of MTHFR as a possible cause of homo-
cystinuria is quite rare. However, several polymorphisms of
MTHFR genes have been reported (polymorphisms means a
mutation with the prevalence of the mutated allele in
populationZ1%). The most studied was the mutation
677C-T (substitution alanine-valine) [2]. This variant of
MTHFR is characteristic with reduced activity in the tem-
perature of 37 1C and increased thermolability in 46 1C, there-
fore it is called thermolabile. As a consequence of this
mutation in a homozygous trait, the specific MTHFR activity
is reduces by 50–60% [4,9]. In a homozygous trait, its pre-
valence is 10–15% in the whites in North America; even 25%
in Hispanic Americans while only 0–1% in Afro-Americans [2].
The presence of this mutation in a homozygous trait may lead
to mild hyperhomocysteinemia in the case of simultaneous
folate deficiency but after folate supplementation the level
drops to normal [4]. Mutation in MTHFR gene 1298 A-C
(substitution glutamine-alanine) is another common poly-
morphism with the prevalence of about 40% in a heterozygous
trait and 10% in a homozygous trait [4], it leads to the decrease
of MTHFR activity by 35% [9].4. Prothrombotic effects of homocysteine
The association of hyperhomocysteinemia with thrombosis
may be explained by multifactorial mechanism, generally by
the impaired balance between procoagulation and anticoa-
gulation factors. Nevertheless, it is important to realize that
most of our knowledge about homocysteine effects originated
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hymocysteine concetrations and therefore, it is questionable
whether the results of those in vitro studies might be extra-
polated into clinical practice. Another research source is
animal models with diet-induced hyperhomocysteinemia. In
this case, potential metabolic differences between animals
and humans should be taken into consideration. Prothrombo-
tic properties of homocysteine were also documented in blood
samples obtained from individuals with various homocysteine
levels.
Various effects of hyperhomocysteinemia have been
reported in the literature so far—Table 2; however, not all of
them are supported by convincing and consistent evidence.
Hyperhomocysteinemia may cause endothelial dysfunction
to the extent comparable to dysfunction induced by hyperch-
olesterolemia and arterial hypertension. The mechanism is
not completely understood, the most probable is the link with
increased oxidative stress. Further on, hyperhomocysteine-
mia may influence multiple components of hemostatic pro-
cess [3,4,10,11].
On the other hand, there are also some data that do not
confirm procoagulant effect of mild hyperhomocysteinemia [11].5. Hyperhomocysteinemia as a risk factor for
VTE
As mentioned above, thromboembolic events are leading
cause of morbidity and mortality in patients with congenital
homocystinuria, a rare disorder with extremely high homo-
cysteine levels. In the affected individuals, both arterial and
venous thrombotic events occur at young age (under 30 years),Table 2 – Multiple effects of hyperhomocysteinem
Vascular endothelium End
– Im
– Pr
en
Platelets Incr
Incr
Fibrinolysis Imp
– De
– De
– In
in
Coagulation factors and natural inhibitors of
coagulation
Incr
Incr
Dec
Incr
Dec
Incr
Fibr
Inhi
Inhieven in early childhood, as was documented in case reports
from the end of the sixties of the last century [12,13].
Even mild to moderate hyperhomocysteinemia may have
clinical consequences, there are reports about association
with coronary artery disease (CAD), stroke, VTE, placentar
vasculopathy, neural tube defects and some neuropsychiatric
diseases [5,14].
The association of hyperhomocysteinemia with VTE has
been studied less extensively than the association with
arterial diseases. The number of studies is lower and the
proved association is weaker, respectively [3]. Moreover,
homocysteine testing in most studies was performed after a
thromboembolic event. Therefore, it remains unclear
whether homocysteine is a direct etiologic factor or a labora-
tory marker. The studies dealing with the association of
homocysteine with VTE can be divided into several groups
and subgroups:1.ia o
oth
pai
oth
dot
eas
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ino
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bitiThe association of homocysteine levels with venous thromboem-
bolic events
The first case-control study, published in 1991, paradoxi-
cally did not confirm the association between homocys-
teine level and VTE [15].
Metaanalysis from1998 [16], including 9 case-control stu-
dies, demonstrated a significant association between
hyperhomocysteinemia and the first or recurrent throm-
boembolic event (hyperhomocysteinemia was defined as a
level above the mean value of control groupþ2 standard
deviations or as a level above the 95th percentile of a
control group). The authors calculated an odds ratio (OR)
as 2.95 with 95% confidence interval (CI) 2.08–4.17. The risk
was even more significant in patients with the history of
VTE under the age of 60 years—OR 4.37 (95% CI 1.94–9.84).n endothelium and hemostasis [3,4,10,11].
elial dysfunction
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rombotic and proinflammatory phenotype of
helium
ed thromoboxane synthesis
ed platelet reactivity
d fibrinolysis
ased binding of tissue plasminogen activator (tPA)
ased plasmin generation
sed level of thrombin activatable fibrinolysis
itor (TAFI)
ed synthesis of tissue factor (TF)
ed activity of factor VII
ed inactivation of factor Va
ed activation of factor V
ed activity of antithrombin
ed thrombin generation
gen modification
on of thrombomodulin activity
on of protein C activation
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control studies demonstrating a significant association of
hyperhomocysteinemia and VTE [17,18] but, on the other
hand, also prospective studies that had not proved higher
risk of VTE in the individuals with hyperhomocysteinemia
[19]. Quite recent Spanish study of younger VTE patients
(under the age of 55, respectively) without other thrombo-
philia has not confirmed hyperhomocysteinemia (the level
415 mmol/L) as an independent VTE risk factor [20].2. The association of the polymorphisms in MTHFR genes and VTE
Most studies focused on potential association of a
relatively common MTHFR gene mutation 677C-T
which, if inherited in a homozygous trait, means a
predisposition to mild hyperhomocysteinemia. The findings
are inconsistent.
American authors performed a case-control study [21] and
did not confirm this mutation in a homozygous trait as a
genetic predisposition to VTE, neither isolated nor in
combination with factor V Leiden (FVL).
Italian study [22] confirmed that MTHFR gene 677 TT
mutation increased the risk of VTE in the cases without
known clinical provoking factor and without other throm-
bophilia (i.e. FVL, prothrombin gene mutation G20210A,
protein C, protein S or antithrombin deficiency) with
resultant OR 2.57 (p¼0.017).
To the contrary, a Japanese study [23] found out that
MTHFR gene mutation 677TT is a VTE risk factor only in
the presence of other thrombophilia (protein C, protein S
or plasminogen deficiency and lupus anticoagulant,
respectively) with OR 5.99 (95% CI 1.56–22.96), compared
to a control group.
Metaanalysis, published in 2002 [24] included 31 studies
and calculated an OR for MTHFR gene mutation 677 TT
and VTE as 1.2 (95% CI 1.1–1.4), while a little higher OR was
found in the absence of other thrombophilia—OR 1.5 (95%
CI 1.2–1.9). The authors evaluated the association of
MTHFR gene mutation 677 TT with VTE as weak and did
not recommend including MTHFR testing to routine
thrombophilia workup.
Similar results were obtained in a large Dutch MEGA study
(Multiple Enviromental and Genetic Assessment of Risk
Factors for Venous Thrombosis) which included 4375
patients with the first thromboembolic event [25]. The
authors did not confirm a significant association between
MTHFR 677 TT and VTE—OR 0.94 (95% CI 0.81–1.08).
Neither further common MTHFR gene mutation—MTHFR
1298 A-C has been proven as a significant VTE risk
factor [26].3. The association of VTE with both homocysteine level and
MTHFR gene polymorphism
The results are again ambiguous.
A Polish case-control study (with 146 patients) failed to
confirm an association with MTHFR genotypes as well as
with homocysteine level [27].
In another case-control study, including 240 patients with
VTE, hyperhomocysteinemia (level 420 mmol/L) was sig-
nificantly more frequent in the individuals above the age
of 50 years and those with idiopathic (i.e. otherwise unex-
plained) thromboembolic event. However, there was no sig-
nificant difference in the prevalence of MTHFR genemutation677 TT in VTE patients and in the control group [28].
LITE, a large prospective American study (Longitudinal Inves-
tigation of Thromboembolism Etiology) did not prove MTHFR
gene mutation 677 TT as a VTE risk factor as well [29].
However, it found a weak, statistically nonsignificant associa-
tion of homocysteine level and VTE risk—adjusted OR 1.55
(95% CI 0.93–2.58) for the comparison of the highest to the
lowest quintile of homocysteine levels, while the association
was significant in younger individuals (45–64 years)—adjusted
OR 2.05 (95% CI 1.10–3.83).
Another large prospective study, Danish ‘‘Copenhagen City
Heart Study’’ found 25% higher homocysteine levels in the
carriers of MTHFR gene mutation 677 TT, compared to
MTHFR 677 CT or CC genotype; however, the study did not
confirm higher VTE risk in the carriers of this mutation [30].
Metaanalysis published in 2005 revealed interesting findings.
Hyperhomocysteinemia as a VTE risk factor was more
significant in retrospective studies (according to the results
of 24 studies)—the increase of homocysteinemia by 5 mmol/L
was associated with 60% higher VTE risk (OR 1.6, 95% CI
1.10–1.34) while in 3 prospective studies the increase of
homocysteinemia by 5 mmol/L resulted in 27% higher risk
(OR 1.27, 95% CI 1.01–1.59). The metaanalysis evaluated the
impact of MTHFR 677 TT genotype as well—it was slightly
associated with VTE risk, with the increase by 20%, respec-
tively (OR 1.2, 95% CI 1.08–1.32). The association of VTE risk
and MTHFR 677 TT genotype was influenced by geographical
differences—in North America the genotype was not signifi-
cantly associated with VTE risk which might be explained by
higher folate and riboflavin intake [31].
EDITH was a French prospective observational study evaluat-
ing an interaction between genetic and environmental VTE
risk factors. The authors compared 467 patients with the first
unprovoked thromboembolic event to sex- and age-matched
controls. They revealed an independent association of mild
hyperhomocysteinemia, folate deficiency and vitamin B12
deficiency with VTE—OR in multivariate analysis was 1.48
(95% CI 1.05–2.08) for homocysteine415 mmol/L; 3.14 (95% CI
1.35–7.32) for folate level r4,9 nmol/L; and 1.42 (95% CI
1.03–1.98) for vitamin B12 levelr253 pmol/L. MTHFR 677 TT
genotype was not significantly associated with VTE risk—OR
1.13 (95% CI 0.70–1.81). Thus, these results do not prove
MTHFR gene mutation 677 TT as a VTE risk factor but may
indicate potential influence of the deficiency of B vitamins
independently on homocysteine level [32].
HUNT2, a prospective Norwegian–Dutch study followed a
cohort of 66,140 individuals for 7 years, evaluated the
incidence of VTE and the association of VTE risk with
homocysteine level (measured at inclusion) and MTHFR gene
polymorphism 677C-T. While MTHFR 677 TT genotype was
not a risk factor for VTE, hyperhomocysteinemia (level
above the 95th percentile) was a predictor of a thromboem-
bolic event in men (OR 2.17, 95% CI 1.20–3.91) but not in
women [33].4. The association of homocysteine with recurrent VTE
Some older studies confirmed hyperhomocysteinemia as a
risk factor for recurrent thromboembolic events.
In a Dutch study (including 185 patients with a history of
recurrent VTE and 220 controls) the revealed adjusted OR
was 2.0 (95% CI 1.5–2.7) for homocysteine level above the
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obtained for the level measured after methionine load [34].
AUREC (Austrian Study of REcurrent Venous Thromboem-
bolism), a multicenter prospective Austrian study [35],
followed 264 patients after the first idiopathic throm-
boembolic event (i.e. without any association with surgery,
injury, pregnancy, protein C or protein S deficiency, antith-
rombin or plasminogen deficiency, antiphospholipid syn-
drome, systemic lupus erythematosus or malignancy).
Hyperhomocysteinemia was defined as a level above the
95th percentile of a control group, i.e. 8.8 mmol/L in women
and 11.6 mmol/L in men. The authors evaluated the inci-
dence of recurrent VTE after anticoagulation withdrawal.
There was a significant increase of VTE risk in the patients
with hyperhomocysteinemia with relative risk (RR) 2.6
(95% CI 1.1–6.1), adjusted for age, sex and the presence
of FVL.5. Potential synergic effect of homocysteine or MTHFR 677 TT
genotype and other thrombophilias
Again, the results of various studies are inconsistent.
‘‘Physicians´ Health Study’’, a large prospective cohort
study brought quite convincing evidence. It followed
14,916 healthy men. Laboratory tests at inclusion com-
prised also homocysteine level and genetic testing for FVL.
Within 12 years, 145 thromboembolic events occurred.
Hyperhomocysteinemia (level4the 95th percentile, i.e.
17.25 mmol/L) was associated with the increased risk of
idiopathic VTE (not provoked by malignancy, surgery or
injury) with RR 3.4 (p¼0.002), the presence of FVL was
associated with RR 2.3 (p¼0.005) for any VTE event and
3.6 for an idiopathic event (p¼0.0002). The concomitant
presence of hyperhomocysteinemia and FVL lead to a
significant risk increase—RR 9.65 (p¼0.009) for any VTE
and 21.8 (p¼0.0004) for idiopathic VTE [36].
One smaller Italian case-control study in 1997 confirmed a
synergic effect of MTHFR gene mutation 677 TT and FVL
[37]. While MTHFR gene mutation 677 TT itself was not a
significant VTE risk factor, the coexistence with FVL lead
to significant increase of the risk associated with FVL:
OR for MTHFR gene mutation was 0.8, adjusted OR for FVL
6.3 (95% CI 1.6–25.3) and adjusted OR for concomitant FVL
and MTHFR 677 TT genotype was 17.3 (95% CI 2.0–152.9).
Dutch authors evaluated in the group of 171 patients with
the history of recurrent VTE potential interaction between
hyperhomocysteinemia (level 4the 90th percentile of a
control group), MTHFR gene mutation 677C-T, FVL and
prothrombin gene mutation 20210 G-A [38]. The values of
adjusted OR for recurrent VTE were: 1.8 (95% CI 1.1–3) for
hyperhomocysteinemia; 5.1 (95% CI 3.0–8.6) for FVL; 1.8
(95% CI 0.7–4.2) for prothrombin gene mutation; and 1.4
(95% CI 0.7–2.8) for MTHFR gene mutation 677 TT. Signifi-
cant increase of VTE risk was observed if hyperhomo-
cysteinemia was combined with FVL—OR 11.6 (95% CI
3.2–42.5); as well as if FVL combined with MTHFR gene
mutation 677 TT—OR 18.7 (95% CI 3.3–108).
However, a more recent retrospective study, also Dutch,
found only nonsignificantly increased VTE risk for hyper-
homocysteinemia (417 mmol/L)—adjusted RR 1.6 (95%
CI 0.6–4.5). Though the risk was significantly higher in
the presence of other thrombophilia, a comparable riskincrease was observed even in the individuals with other
thrombophilia and normal homocysteine level. The
authors summarized that the main determinant of VTE
risk was rather concomitant thrombophilia than hyperho-
mocysteinemia itself [39].
Quite recently published metaanalysis (including 5 stu-
dies) then concluded that it was impossible to prove any
interaction (neither additive nor multiplicative) between
FVL and hyperhomocysteinemia as well as FVL and
MTHFR gene mutation 677 TT, concerning VTE risk [40].6. Homocysteine and thrombosis at unusual sites
The mentioned studies dealt with potential association of
hyperhomocysteinemia and the most frequent location
of venous thrombosis, i.e. in the legs. In the literature,
there are also some reports about the prevalence of
hyperhomocysteinemia in the patients with thrombosis
at unusual sites. Most of published data, however,
are derived from small studies, isolated case reports or
case series.
 In a small group (31 patients) with thrombosis of the
upper extremity, 5 patients (16.1%) had elevated homo-
cysteine level [41].
 In a case-control study (121 patients and 242 controls),
hyperhomocysteinemia (level 4the 95th percentile of the
control group, i.e. 419.2 mmol/L in men and 415.2 in
women) was associated with fourfold increase of the risk
of cerebral vein thrombosis [42]. Even more significantly
increased risk was observed for the combination of hyper-
homocysteinemia and hormonal contraception—OR 19.5
(95% CI 5.7–67.3).A significant association of hyperhomocysteinemia and
cerebral vein thrombosis was found also in two smaller
case-control studies [43,44]—the values of OR were 4.18
(95% CI 1.58–11.16) and 6.88 (p¼0.002), respectively.
 In a case-control study, searching for the risk factors of
retinal vein occlusion [45], the authors found signifi-
cantly higher prevalence of hyperhomocysteinemia
(413.5 mmol/L) in 132 patients with central retinal vein
thrombosis in comparison to 105 healthy controls, with
resultant OR 8.64 (95% CI 1.96–38.0).
 Some authors also investigated potential associa-
tion between hyperhomocysteinemia and visceral veinthrombosis.
In a study of 65 patients with extrahepatic portal vein
obstruction, the prevalence of hyperhomocysteinemia was
higher in the patients than in the control group [46] but
the difference did not reach statistical significance—OR
2.0 (95% CI 0.9–4.9).
In a small study, including 12 patients with mesenteric vein
thrombosis, the authors found a significant association of
MTHFR 677 TT genotype, in comparison to healthy con-
trols [47].7. Correction of hyperhomocysteinemia by vitamin supplementation
Homocysteinemia correlates inversely with the level of folate,
vitamin B12 and, to a lesser extent, vitamin B6 [48]. Supple-
mentation by these vitamins is therefore a possibility how to
reduce or even normalize homocysteine level.
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various doses of these vitamins in the reduction of homo-
cysteine level. It evaluated the results of 12 studies including
1114 individuals. The highest effect on homocysteinemia
reduction was reached by folic acid administration. The
higher was homocysteine level and the lower was folate level
prior to supplementation, the higher was the reduction of
homocysteine level. There was no difference in the effect in
the dose range 0.5–5mg of folic acid daily—the consequence
was a drop in homocysteinemia by 25%.Vitamin B12 in the
mean dose 0.5mg led to an additional level drop by 7% while
vitamin B6 (in the mean dose 16.5mg daily) had no further
additional effect [49].
These findings were later confirmed by further, more exten-
sive metaanalysis of 25 studies, including 2596 individuals.
Maximal reduction of homocysteine level (by 23–25%) was
reached by folic acid, administered in daily dose Z0.8 mg;
additional level reduction (by 7%) was achieved by the
concomitant medication with vitamin B12 in daily dose
0.4mg. Again, vitamin B6 did not prove any significant
additional effect [50].
In some specific situation, e.g. chronic renal insufficiency,
higher doses of folic acid are necessary to reduce homocys-
teinemia [3]. Uncertainty may also exist in the patients with
medication which causes increase of homocysteine level but
the data about vitamin dosing in these cases are quite scarce.
In a study of the patients with rheumatoid arthritis on
metothrexate, supplementation with folic acid 1mg daily
led to a significant drop of homocysteinemia [51]. Fenofibrate
use may increase homocysteine level by 40%. German
authors demonstrated that this increase may be prevented
by comedication with folic acid (0.65mg daily), vitamin B12
(50 mg daily) and B6 (5mg daily) [52,53]. A Norwegian study
proved the effect of vitamin supplementation (in daily doses
of 0.4mg of folic acid, 120mg of vitamin B6 and 75mg of
riboflavin) on the reduction of hyperhomocysteinemia
induced by antiepileptics [54].8. Interventional studies—the effect of reducing homocysteine
levels on VTE risk
Hence, vitamin supplementation is effective in the reduc-
tion of homocysteine level but clinical benefit (i.e. the
efficacy of vitamin supplementation in VTE prevention) is
questionable.
Severe hyperhomocysteinemia—e.g. in homocystinuria
requires undoubtedly vitamin therapy. In a multicenter study,
158 patients with homocystinuria (caused by CBS deficiency)
were treated by vitamins (folic acid, vitamin B6, vitamin B12,
betaine) and a low-methionine diet and the incidence of
vascular events was compared to a historic cohort of 629
patients without any supplementation. Vitamin supplemen-
tations led to a significant reduction, though not complete
normalization of homocysteine levels. It resulted in signifi-
cant reduction of the risk of vascular events, including
thromboembolic events [55].
Nevertheless, the evidence about indication of vitamin ther-
apy in mild to moderate hyperhomocysteinemia is much less
convincing. The authors of metaanalysis of 92 studies,
evaluating the risk of CAD, stroke and VTE in association
with hyperhomocysteinemia calculated that the drop of
homocysteine level by 3 mmol/L should result in 25%reduction of VTE risk [56]. However, this assumption has not
been proven in prospective studies.
Secondary analysis of HOPE-2 study (including 5,522 indivi-
duals at the age above 55 years with cardiovascular disease or
diabetes mellitus and at least one vascular risk factor)
reported the results of 5 year follow-up of the group with
vitamin therapy (2.5mg of folic acid, 50mg of vitamin B6 and
1mg of vitamin B12 daily) in comparison to placebo group
[57]. Vitamin supplementaion was effective in homocysteine
level reduction but not in VTE risk reduction—hazard ratio
(HR) 1.01 (95% CI 0.66–1.53).
The efficacy of vitamin therapy and homocysteine reduc-
tion in secondary VTE prevention was evaluated in VITRO
study (The Vitamins and Thrombosis), which included 701
patients with the first episode of unprovoked DVT or PE.
The effect of vitamin supplementation (in the daily doses
of 5 mg of folic acid, 50mg of pyridoxine and 0.4 mg of
vitamin B12) was compared to placebo in two groups—‘‘hy-
perhomocysteinemic’’ (with homocysteine level above the
75th percentile of reference group, i.e.Z12.6 mmol/L) as well
as ‘‘normohomocysteinemic’’. The follow-up lasted 2.5
years and the observed HR for VTE recurrence associated
with vitamin therapy was 1.14 (95% CI 0.65–1.98) for the
‘‘hyperhomocysteinemic’’ group, and 0.58 (95% CI 0.31–1.07)
for the ‘‘normohomocysteinemic’’ group [58].
Accordingly, the benefit of vitamin supplementation is uncer-
tain. Though this therapy is not too expensive and is
relatively safe it is important to realize some potential risks
as well. High doses of vitamin B6 may cause peripheral
sensory neuropathy. Further on, long term administration of
folic acid in high doses may impair blood–brain barrier. [59].6. Homocysteine—culprit or innocent
bystander?
There are some hypotheses trying to explain the unconvincing
and inconsistent results of the mentioned studies:– the studies with vitamin supplementation were mostly
performed in the countries with folate-fortified diet, i.e.
homocysteine level prior to supplementation was
relatively low– B vitamins may theoretically have a harmful effect which
outweighs their potential benefit [7]– hyperhomocysteinemia
 is not a cause but a marker of VTE event
 is only a marker of vitamin B deficiency
 if mild, is associated only with a small absolute
VTE risk
 is a VTE risk factor only in very high concentrations
 is a risk factor only if combined with other additional
risk factors [2,3,7]
 is not a real VTE risk factor but the true risk factor is some
other pathology associated with hyperhomocysteinemiaFor example, Dutch authors discovered an association of
hyperhomocysteinemia and high factor VIII level which they
considered the proper risk factor of arterial and venous
thrombosis [60,61].
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after fibrate therapy [62]. It may be theoretically explained by
fibrate-induced hyperhomocysteinemia [63]. However, this
hypothesis is in contradiction with the results of a French
study (including 677 patients with unprovoked VTE event and
677 controls), which revealed significantly higher association
of VTE with fibrate use but this association was independent
on homocysteine level [64].7. Guidelines
Insufficient data indicative of a causative association between
hyperhomocysteinemia and VTE and unconvincing evidence
about the efficacy of homocysteine lowering therapy in primary
and secondary VTE prevention result in the absence of clear and
actual guidelines for testing homocysteine or therapy of hyper-
homocysteinemia in the patients with VTE event, or in the
individuals with higher thromboembolic risk.
In the ACCP guidelines for antithrombotic therapy (American
College of Chest Physicians—ACCP Conference on Antithrombo-
tic and Thrombolytic Therapy) from 2004, hyperhomocysteine-
mia was mentioned as risk factor for VTE recurrence. For the
patients with the first thromboembolic event and some throm-
bophilic disorders – including hyperhomocysteinemia – the
authors recommended prolonged anticoagulation (6–12months),
and this recommendation was labeled with 1A [65]. However,
folic acid supplementation was recommended only in pregnant
women with hyperhomocysteinemia, but not for VTE prophy-
laxis but because of the risk of spontaneous abortion [66].
However, ACCP Guidelines have been later updated every 4
years. In the following edition in 2008, neither hyperhomocys-
teinemia nor other thrombophilic disorders were considered a
significant factor in making the decision about the length of
anticoagulation [67]. Hyperhomocysteinemia was mentioned as
a potential risk factor of abortion but recommendation concern-
ing vitamin supplementation is absent in this edition [68].
Similarly, in the recent edition of ACCP Guidelines from
2012, hereditary thrombophilias are considered only addi-
tional risk factor for VTE recurrence and hyperhomocystei-
nemia itself is not particularly mentioned [69]. In the chapter
about VTE and thrombophilic disorders in pregnancy, the
authors deal with homozygous MTHFR 677 TT mutation.
They note that the association of this mutation with VTE in
pregnancy was not proved which might be explained by
physiologic decrease of homocysteine level in pregnancy
and by common folic acid supplementation in pregnancy
(in the indication of neural tube defect prevention). The
association with pregnancy morbidity is also mentioned but
the authors do not comment on the necessity of vitamin B
supplementation in this indication [70].
Due to the absence of recent guidelines concerning homo-
cysteine and VTE, it might be useful to take into considera-
tion some older recommendations.
Back in 2002, the American consensus about thrombophi-
lic disorders considered testing homocysteine level in VTE as
controversial. From the laboratory point of view, two methods
were suggested—high performance liquid chromatography as
well as immunoanalysis [4].Homocysteine testing is mostly recommended in the
fasting state. However, level fluctuation usually does not
exceed 10% of the basal value. Therefore, in the practice,
fasting might not be so strictly required [1]. In the case of
abnormal homocysteine level in non-fasting state, testing the
fasting level could be performed later. Neither homocysteine
measuring after methionine load is routinely recommended
in the practice [2].
It is not quite clear whether a thromboembolic event itself
does not induce elevated homocysteine level. Therefore, it
seems prudent to postpone the testing after the acute VTE
event and to perform it 6 months later [4].
Testing MTHFR gene 677 or 1298 mutations in VTE
patients is still sometimes performed but should be aban-
doned [71].
Testing homocysteine level might be indicated in the
cases of idiopathic or recurrent VTE, DVT or PE at young age
or thrombosis at unusual sites. Vitamin supplementation
might be suitable in the patients with proven folate or
vitamin B12 deficiency [31], and in those with some addi-
tional VTE risk factor [2]. However, the patients should be
informed about the uncertain benefit of this treatment in the
prevention of VTE recurrence [72]. Rational diet with suffi-
cient content of fruit and vegetables is a possible alternative
of pharmacologic vitamin supplementation [2]. The value up
to10–12 mmol/L is recommended as a target homocysteine
level [3].
In the last British guidelines for diagnosis and treatment
of thrombosis at unusual sites, hyperhomocysteinemia is
mentioned as a risk factor of retinal vein occlusion [73] but
the authors do not recommend thrombophilia testing (hence,
neither homocysteine testing).8. Conclusion
The association of hyperhomocysteinemia and VTE is con-
troversial. It is possible that thrombosis risk is influenced by
the interaction of homocysteine metabolism disorders, vita-
min levels and further prothrombotic factors. So far, the data
have not brought enough evidence about the benefit of
vitamin supplementation in the individuals with mild hyper-
homocysteinemia in the primary and secondary VTE preven-
tion [2,3]. Further studies might be required to prove the
causative association between hyperhomocysteinemia and
VTE, as well as randomized clinical trials to confirm signifi-
cant VTE risk reduction due to homocysteine lowering by
vitamin therapy. Meanwhile, it is necessary to choose quite a
conservative approach to the problem of homocysteine and
venous thrombosis and to consider carefully homocysteine
level management in selected cases.Acknowledgements
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